Advanced Search
WU Haibing, ZHAO Xiaoyan, SHEN Mingfang, Huang Rui, CHEN Cheng, REN Tao, SHEN Yang. Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 462-465. DOI: 10.3971/j.issn.1000-8578.2020.19.1364
Citation: WU Haibing, ZHAO Xiaoyan, SHEN Mingfang, Huang Rui, CHEN Cheng, REN Tao, SHEN Yang. Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 462-465. DOI: 10.3971/j.issn.1000-8578.2020.19.1364

Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients

More Information
  • Corresponding author:

    SHEN Yang, E-mail:13905737152@163.com

  • Received Date: October 31, 2019
  • Revised Date: March 15, 2020
  • Available Online: January 12, 2024
  • Objective 

    To explore the clinical value of new high-throughput drug sensitivity (HDS) screening technology in the individualized medication of relapsed refractory acute myeloid leukemia patients.

    Methods 

    We collected bone marrow samples of 19 patients with relapsed and refractory acute myeloid leukemia, enriching and culturing leukemic cancer cells by HDS technology. In vitro efficacy evaluation of 15 single drugs and 17 chemotherapy regimens was carried out according to the blood peak concentration corresponding to clinical dose. The drugs and programs were divided into four levels: high, medium, low and insensitive, according to the inhibition rate of cell activity detected and calculated by Celltiter-Glo based chemiluminescence, then we observed the clinical remission rate.

    Results 

    Among the 19 patients, there were 4 cases of non-remission (NR), 4 cases of complete remission (CR) and 11cases of partial remission (PR), and the overall remission rate was 78.94%. The sensitivity frequency of DAE, DAC, HAD and HD-DA schemes were higher than 68%.

    Conclusion 

    The high-throughput drug sensitivity screening technology is a rapid, efficient and low-cost detection technology, with good clinical application value in individualized medication of relapsed refractory AML patients, worthy of clinical promotion in the post genomic era.

  • [1]
    Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells[J]. Nature, 2012, 483(7391): 570-575. doi: 10.1038/nature11005
    [2]
    Pemovska T, Kontro M, Yadav B, et al. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia[J]. Cancer Discov, 2013, 3(12): 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
    [3]
    Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer[J]. Science, 2014, 346(6216): 1480-1486. doi: 10.1126/science.1254721
    [4]
    Chia S, Low JL, Zhang X, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time[J]. Nat Commun, 2017, 8(1): 435. doi: 10.1038/s41467-017-00451-5
    [5]
    Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia[J]. Nature, 2018, 562(7728): 526-531. doi: 10.1038/s41586-018-0623-z
    [6]
    Pemovska T, Kontro M, Yadav B, Edgren H, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia[J]. Cancer Discov, 2013, 3(12): 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
    [7]
    Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia[J]. J Clin Oncol, 2004, 22(16): 3432-3433. doi: 10.1200/JCO.2004.99.116
    [8]
    Marquart J, Chen EY, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology[J]. JAMA Oncol, 2018, 4(8): 1093-1098. doi: 10.1001/jamaoncol.2018.1660
    [9]
    Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261. doi: 10.1038/s41586-019-0987-8
    [10]
    Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics[J]. Nat Rev Cancer, 2015, 15(12): 747-756. doi: 10.1038/nrc4015
    [11]
    Yan X, Zhou L, Wu Z, et al. High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing[J]. Biomaterials, 2019, 198: 167-179. doi: 10.1016/j.biomaterials.2018.05.020
    [12]
    朱路, 勾越阳, 鄢晓君, 等.基于病人自体肿瘤细胞体外培养模型的个体化精准用药[J].中国医疗设备, 2016, 31(6): 13-18, 35. doi: 10.3969/j.issn.1674-1633.2016.06.003

    Zhu L, Gou YY, Yan XJ, et al. Precise medicine in cancer treatmentvia patient derivedin vitro tumor model[J]. Zhongguo Yi Liao She Bei, 2016, 31(6): 13-18, 35. doi: 10.3969/j.issn.1674-1633.2016.06.003
    [13]
    刘飞扬, 黄瑞, 任涛, 等.肿瘤精准用药治疗的技术体系[J].高科技与产业化, 2016, 242: 50-52. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gkjycyh201607007

    Liu FY, Huang R, Ren T, et al. Technology system of cancer Precision medicine[J]. Gao Ke Ji Yu Chan Ye Hua, 2016, 242: 50-52. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gkjycyh201607007
    [14]
    Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells[J]. Am J Pathol, 2012, 180(2): 599-607. doi: 10.1016/j.ajpath.2011.10.036
    [15]
    Almosailleakh M, Schwaller J. Murine Models of Acute Myeloid Leukaemia[J]. Int J Mol Sci, 2019, 20(2). pii: E453. doi: 10.3390/ijms20020453
    [16]
    Mazzocchi AR, Rajan SAP, Votanopoulos KI, et al. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening[J]. Sci Rep, 2018, 8(1): 2886. doi: 10.1038/s41598-018-21200-8

Catalog

    Article views (1399) PDF downloads (312) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return